A Prospective Study of SCA3 Gait Ataxia Described through a Markovian MethodCamey S.a · Jardim L.B.b, c · Kieling C.d · Saute J.A.M.e · Vigo Á.a
Departments of aStatistics and bInternal Medicine, Universidade Federal do Rio Grande do Sul, and Departments of cMedical Genetics, dPsychiatry and eNeurology Services, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Studies on the natural history of rare, chronic diseases like spinocerebellar ataxia 3 (SCA3) are hard to be done, since patients enter the study with variable disease durations and are followed up at irregular intervals. Aims: Our purpose was to use all the available data to describe the progression of gait ataxia in a long-term cohort of patients with SCA3 through a markovian method. Materials and Methods: SCA3 patients were recruited between 1998 and 2005 and were invited to annual neurological follow-ups until 2007. Gait ataxia was described through a mean score graph and a mean trajectory graph. Results: We followed up 105 patients; at baseline, the mean age and disease duration were, 40.5 (SD = 12.6) and 7.7 (SD = 5.8) years, respectively. The mean time to reach stages 1, 2, 3 and 4 of gait ataxia were 3, 5.4, 10.8 and 19.4 years of disease duration. The mean score graph was unsmooth, showing several unlikely ups and downs. The mean trajectory graph produced a continuous curve. Conclusion: The markovian method described the natural history of gait ataxia without any a posteriori adjustment of data and allowed statistical comparisons between subgroups. This method will be useful in future clinical trials in this and in other chronic degenerative diseases.
© 2010 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.